Top stories for World Psoriasis Day: ‘More than a day for awareness’
Click Here to Manage Email Alerts
Since 2004, World Psoriasis Day has been celebrated on Oct. 29.
This year’s theme from the International Federation of Psoriasis Associations (IFPA) is “connected.”
“World Psoriasis Day is more than a day for awareness; it is a global campaign that allows individuals, patient organizations, civil society, health care professionals and other stakeholders to take action on behalf of people with psoriasis and psoriatic arthritis — action that can drive change and bring positive developments to the lives of millions of people,” according to a press release from the IFPA.
Below are the most popular news stories in psoriasis research and management at Healio Dermatology.
Taltz meets primary, secondary endpoints in head-to-head trial
The IXORA-R trial represents the first completed head-to-head trial between an interleukin-17A inhibitor and an IL-23/p19 inhibitor using the Psoriasis Area Severity Index (PASI) 100 score as the primary endpoint, according to the press release. Read more
Guselkumab shows superior long-term efficacy vs. secukinumab based on PASI 90
A significantly greater proportion of patients with psoriasis receiving guselkumab achieved a 90% reduction or more in the PASI at week 48 than those receiving secukinumab, according to researchers in The Lancet. Read more
Women of childbearing age with psoriasis require pregnancy friendly treatment plan
As half of all pregnancies go unplanned, patients and providers must understand the implications of therapeutic options in all women with psoriasis who are sexually active, whether or not they plan to start a family, according to researchers. Read more
With perspective from Junko Takeshita, MD, PhD, MSCE.
UCB reports bimekizumab response rates superior to Stelara in psoriasis
Treatment with bimekizumab, an interleukin-17A and IL-17F inhibitor in adults with chronic plaque psoriasis, resulted in at least a 90% improvement in the PASI and Investigator Global Assessment score of clear or almost clear, according to phase 3 results from the development program BE VIVID by UCB. Read more
4-year data demonstrate safety, efficacy of Ilumya in plaque psoriasis
The safety and efficacy of Ilumya were maintained after 4 years of treatment among patients with plaque psoriasis enrolled in the open-label reSURFACE1 trial, according to data presented at the European Academy of Dermatology and Venereology Congress. Read more
Joint guidelines explore best practices in NB-UVB therapy for psoriasis
Based on the available literature, the American Academy of Dermatology and the National Psoriasis Foundation published joint guidelines on ultraviolet light-based therapies for the treatment of psoriasis. Read more
With perspective from Alan Menter, MD.
Some patients prescribed biologics also receive topical medications for psoriasis
In patients with psoriasis, the median time between first and last biologic prescriptions was between 3.3 and 7 months with up to 50% of patients not prescribed a second prescription for the medication, according to researchers in Journal of Drugs in Dermatology. Read more
Amgen to acquire Otezla, pending Celgene merger
Amgen has entered into an agreement with Celgene to acquire worldwide rights to Otezla for $13.4 billion in cash, or approximately $11.2 billion, net of the present value of $2.2 billion in anticipated future cash tax benefits. Read more